Navrogen Raises $3.0M in Seed Funding
- Navrogen, Inc., a Cheyney, Pa.-based preclinical biotechnology company, raised $3.0M in equity financing
- The financing was led by Tellus BioVentures along with existing investors
- As part of the financing, Lonnie Moulder, Managing Member of Tellus, and Allan Bedwick, will join the company Board of Directors
- The company intends to use the funds to advance its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities
- The company is a biotechnology company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that are associated with suppressed humoral immunity
- The company’s mission is to develop first-in-class agents that can overcome the immunosuppressive effects of HIO factors by employing its proprietary screening and engineering technologies
